Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG-Reference-Cited by-同舟云学术

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG

Published:2014-02-27 Issue:6 Volume:22 Page:586-595
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Kuroi Katsumasa,Toi Masakazu,Ohno Shinji,Nakamura Seigo,Iwata Hiroji,Masuda Norikazu,Sato Nobuaki,Tsuda Hitoshi,Kurosumi Masafumi,Akiyama Futoshi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-014-0524-4.pdf

Reference23 articles.

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.

2. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927–34.

3. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer. 2006;13:38–48.

4. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother. 2005;59:S387–92.

5. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011;2011:147–51.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts;Translational Oncology;2024-10

2. Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306;Breast Cancer Research and Treatment;2024-06-27

3. Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: An ancillary study of JCOG0306;2024-04-11

4. Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival;The Breast;2023-12

5. Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer;Cancer Investigation;2023-10-21